You are here

About EJC

The European Journal of Cancer (EJC) is an international multidisciplinary oncology journal. EJC publishes original research, reviews and editorial comments on a wide range of oncology disciplines, including basic and preclinical cancer research, translat

In addition to research and reviews, every month the journal also publishes EJC News Focus, a series of video interviews with key opinion leaders in oncology.

The EJC is included in the leading abstracting and indexing services, such as PubMed/MEDLINE, Current Contents/Clinical Medicine, the Science Citation Index, the Journal Citation Reports and Scopus.

The EJC is the official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO), the European Association for Cancer Research (EACR) and the European Society of Breast Cancer Specialists (EUSOMA).

Publishing in EJC

EJC provides authors with a number of benefits. Efficient peer-review contributes to fast publication times, with all manuscripts accepted for publication being published online – citable and indexed – within four to five weeks of acceptance. Authors can also enhance their articles with a number of Content Innovations, including AudioSlides, the Database Linking Tool and Gene Expression Omnibus Linked Data.

Reading EJC

Published in print and online, the EJC is available to more than 17,000 academic and clinical institutions, personal subscribers and members of the journal's Society Partners.

Readers can also access EJC via an iPad app and sign up for free eTables of Contents via email, which are sent out for each issue of the journal.

Register for the E-Alert


We would like to know what challenges you face in treating patients with advanced breast cancer.

Send us your feedback and take this opportunity to submit your questions to our faculty.

Educational need

Clinicians have an unmet need to understand the mechanisms underlying CDK4&6 inhibition, the rationale for using CDK4&6 inhibitors to treat advanced breast cancer, and the clinical data supporting the use of CDK4&6 inhibitors in the treatment of advanced breast cancer.

Made possible by an educational grant from